摘要新辅助治疗已成为临界可能切除和局部进展期胰腺癌的标准治疗之一，但其可能在控制肿瘤进展的同时加重胰腺癌患者的营养不良，从而影响这部分患者的术后结局及长期预后。通过回顾相关文献发现，新辅助治疗会在不同程度上造成患者术前营养状况恶化，但及时有效的营养干预可改善这种情况。这也提示有必要对接受新辅助治疗的患者进行早期营养干预以改善预后。但鉴于目前相关研究有限，且均存在一定局限性，未来仍需更多严谨、系统的研究来阐明问题，为早期对行新辅助治疗的胰腺癌患者进行有效的营养干预提供依据。

abstractsNeoadjuvant therapy has been one of the standard therapies for borderline resectable pancreatic cancer and locally advanced pancreatic cancer, but it may deteriorate these patients′ nutritional status while controlling the progress of cancer, which inevitably influences these patients′ postoperative outcomes and prognosis.In this article, we tried to answer this problem by reviewing other studies.And we found that neoadjuvant therapy would influence patients′ postoperative outcomes and prognosis by deteriorating their nutritional status.But effective nutritional support can prevent it.It indicates that there is a need for these patients to receive nutritional support as soon as possible.However, in consideration of the limited number of relevant studies and their limitations, there is a need for more studies with strict design to answer this problem.And it can provide evidence for early nutritional support in pancreatic cancer patients who is going to undergo neoadjuvant therapy.